Buscar
Mostrando ítems 1-1 de 1
Artículo
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
(Original Research, 2019)
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from followup periods longer than 1 year are still ...